Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/175427
Title: Ecto-GPR37: a potential biomarker for Parkinson’s disease
Author: Morató Arús, Xavier
Garcia Esparcia, Paula
Argerich, Josep
Llorens Torres, Franc
Zerr, Inga
Paslawski, Wojciech
Borràs, Eva
Sabidó, Eduard
Petäjä-Repo, Ulla E.
Fernández Dueñas, Víctor
Ferrer, Isidro (Ferrer Abizanda)
Svenningsson, Per
Ciruela, Francisco
Keywords: Malaltia de Parkinson
Marcadors bioquímics
Parkinson's disease
Biochemical markers
Issue Date: 26-Feb-2021
Publisher: Springer Nature
Abstract: Objective: α-Synuclein has been studied as a potential biomarker for Parkinson's disease (PD) with no concluding results. Accordingly, there is an urgent need to find out reliable specific biomarkers for PD. GPR37 is an orphan G protein-coupled receptor that toxically accumulates in autosomal recessive juvenile parkinsonism. Here, we investigated whether GPR37 is upregulated in sporadic PD, and thus a suitable potential biomarker for PD. Methods: GPR37 protein density and mRNA expression in postmortem substantia nigra (SN) from PD patients were analysed by immunoblot and RT-qPCR, respectively. The presence of peptides from the N-terminus-cleaved domain of GPR37 (i.e. ecto-GPR37) in human cerebrospinal fluid (CSF) was determined by liquid chromatography-mass spectrometric analysis. An engineered in-house nanoluciferase-based immunoassay was used to quantify ecto-GPR37 in CSF samples from neurological control (NC) subjects, PD patients and Alzheimer's disease (AD) patients. Results: GPR37 protein density and mRNA expression were significantly augmented in sporadic PD. Increased amounts of ecto-GPR37 peptides in the CSF samples from PD patients were identified by mass spectrometry and quantified by the in-house ELISA method. However, the CSF total α-synuclein level in PD patients did not differ from that in NC subjects. Similarly, the cortical GPR37 mRNA expression and CSF ecto-GPR37 levels in AD patients were also unaltered. Conclusion: GPR37 expression is increased in SN of sporadic PD patients. The ecto-GPR37 peptides are significantly increased in the CSF of PD patients, but not in AD patients. These results open perspectives and encourage further clinical studies to confirm the validity and utility of ecto-GPR37 as a potential PD biomarker.
Note: Reproducció del document publicat a: https://doi.org/10.1186/s40035-021-00232-7
It is part of: Translational Neurodegeneration, 2021, vol. 10
URI: http://hdl.handle.net/2445/175427
Related resource: https://doi.org/10.1186/s40035-021-00232-7
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Patologia i Terapèutica Experimental)

Files in This Item:
File Description SizeFormat 
s40035-021-00232-7.pdf1.72 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons